Qualigen Therapeutics, soon to be rebranded as CXC10, is transitioning its focus to cryptocurrency and Web3-related business activities. The company will concentrate on developing C10 value anchor products, including treasury and index services, a DeAI Agent for trading optimization, and ecosystem tokens, with plans for a potential stablecoin.